300 million doses will be produced and available next fall.
And the injection of cloned antibodies that interfere with COFED19 can be important for people in the early stages of infection, according to the Swedish-British drug company AstraZeneca.
Pascal Suryot, director of the Swedish-British pharmaceutical company, told the British “Daily Telegraph” that the treatment being developed was “a combination of two antibodies” in a syringe dose, “because by having both, it reduces the chances of resisting the development of one antibody.”
Antibody therapy is more expensive than producing a vaccine, with Sariot saying: The first will give priority to the elderly and vulnerable, “who may not be able to develop a good response to the vaccine.”
Reports revealed that the company last Thursday signed a deal with the “Alliance for Pandemic Preparedness Innovations” to help manufacture 300 million doses accessible globally, for a possible vaccine against the Corona virus.
It will allow the manufacture of the Oxford University vaccine against “Covid 19” to ensure that it is available in the fall if it passes human trials. Potential vaccine trials were started in Brazil, with a new epidemiological center, to ensure that the study could be properly tested with lower transmission rates in the UK. The Oxford vaccine group began developing a vaccine in January.
Follow the world news from the statement through Google News
Source link to the news